君实生物(688180) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥485,143,734.52, representing a 53.16% increase compared to the same period last year[2]. - The net profit attributable to shareholders was -¥281,813,873.94 for Q3 2024, with a year-to-date net profit of -¥926,768,557.18[2]. - The company's revenue for the first three quarters of 2024 reached approximately RMB 1.27 billion, a year-on-year increase of about 29% compared to RMB 986.46 million in the same period of 2023[14]. - Total revenue for the first three quarters of 2024 reached ¥1,334,950,275.33, an increase from ¥994,903,657.69 in the same period of 2023, representing a growth of approximately 34.3%[18]. - Net profit for the third quarter of 2024 was reported at -¥988,725,690.94, an improvement compared to -¥1,555,128,891.35 in the third quarter of 2023, indicating a reduction in losses by about 36.4%[17]. - Operating profit for the third quarter of 2024 was -¥969,121,005.27, an improvement from -¥1,580,362,717.66 in the previous year, showing a decrease in operating losses by about 38.5%[16]. - Total comprehensive income for the third quarter of 2024 was -¥1,036,670,389.84, compared to -¥1,605,861,657.78 in the same quarter of 2023, reflecting a decrease in comprehensive losses by about 35.3%[17]. - The company reported a basic and diluted earnings per share of -¥0.94 for the third quarter of 2024, an improvement from -¥1.43 in the same quarter of 2023[17]. Research and Development - Research and development (R&D) expenses totaled ¥327,892,775.06 in Q3 2024, accounting for 67.59% of operating revenue, a decrease of 34.07 percentage points year-on-year[3]. - The company is focusing on enhancing cost control and reallocating resources to more promising R&D projects, leading to a reduction in losses[6]. - The company’s core product, Tuoyi®, has reached key clinical trial endpoints, contributing to revenue growth in chemical drug sales[6]. - The core product Tuoyi® (Tislelizumab) generated sales revenue of approximately RMB 1.068 billion in the domestic market, representing a year-on-year growth of about 60%[12]. - The company has received approval for 10 indications of Tislelizumab in mainland China and has also gained approvals in regions including Hong Kong, the US, and the EU[12]. - The company plans to accelerate the development and application for later-stage pipelines, including anti-tumor antibodies and other innovative drugs, to drive future revenue growth[12]. - The company has received regulatory approval for the clinical trial application of the HDACs inhibitor WJ47156, indicating ongoing innovation efforts[12]. - Research and development expenses decreased to ¥874,268,925.53 from ¥1,270,626,649.07, reflecting a reduction of approximately 31.1%[16]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 29,498[7]. - The total number of ordinary shareholders reached 29,489 by the end of the reporting period[9]. - HKSCC NOMINEES LIMITED holds 219,291,210 shares, accounting for 22.25% of total shares[8]. - The top 10 shareholders collectively hold 490,000,000 shares, representing approximately 49.0% of total shares[10]. - The company reported a total of 87,854,018 shares held by shareholder Xiong Jun, which is 8.91% of total shares[8]. - The investment fund managed by China Industrial Bank holds 25,295,724 shares, accounting for 2.57% of total shares[9]. - The company has no shareholders participating in margin trading as of the reporting period[9]. - The shareholding structure indicates a family relationship between major shareholders, Xiong Jun and Xiong Fengxiang, who are father and son[9]. - The company has not disclosed any other related party relationships among the top shareholders[9]. - The total number of shares held by the top 10 unrestricted circulating shareholders is 490,000,000[10]. - The company has not reported any changes in the top 10 shareholders due to margin trading activities[11]. Cash Flow and Assets - The company reported a net cash flow from operating activities of -¥1,113,472,084.61 year-to-date[2]. - Cash flow from operating activities for the first three quarters of 2024 was -¥1,113,472,084.61, an improvement from -¥1,664,114,192.65 in the same period of 2023, indicating a reduction in cash outflow by approximately 33.1%[19]. - Cash and cash equivalents, along with trading financial assets, totaled RMB 3.045 billion, indicating a strong liquidity position[12]. - Cash and cash equivalents at the end of the third quarter of 2024 stood at ¥2,474,334,261.64, down from ¥4,141,718,242.77 at the end of the third quarter of 2023[19]. - The total assets at the end of Q3 2024 were ¥10,857,613,524.70, down 4.28% from the end of the previous year[3]. - The company’s total assets decreased to approximately RMB 10.858 billion as of September 30, 2024, down from RMB 11.343 billion at the end of 2023[14]. - The total liabilities as of September 30, 2024, amounted to approximately RMB 4.578 billion, an increase from RMB 4.022 billion at the end of 2023[14]. - The company's operating costs for the first three quarters of 2024 were approximately RMB 2.261 billion, a decrease from RMB 2.479 billion in the same period of 2023[14]. - The company’s investment activities generated a net cash outflow of -¥1,083,510,749.67 for the first three quarters of 2024, compared to -¥653,834,246.14 in the same period of 2023, indicating an increase in investment outflows[19]. Financial Ratios - The weighted average return on net assets was -4.45%, an increase of 0.46 percentage points compared to the previous quarter[3]. - The company’s financial expenses included interest expenses of ¥32,912,225.93, an increase from ¥19,975,951.59 in the previous year[16].